MNG308
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.477
- MYC_TARGETS_V1+0.438
- MITOTIC_SPINDLE+0.411
- UV_RESPONSE_DN+0.402
- UNFOLDED_PROTEIN_RESPONSE+0.396
- MYC_TARGETS_V2+0.391
- E2F_TARGETS+0.383
- WNT_BETA_CATENIN_SIGNALING+0.368
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.366
- PROTEIN_SECRETION+0.331
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.311
- KRAS_SIGNALING_DN-0.138
- PANCREAS_BETA_CELLS-0.136
- INTERFERON_GAMMA_RESPONSE-0.128
- OXIDATIVE_PHOSPHORYLATION-0.128
- P53_PATHWAY-0.102
- PEROXISOME-0.074
- COAGULATION-0.061
- XENOBIOTIC_METABOLISM-0.050
- BILE_ACID_METABOLISM-0.047
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BDEB76B7-B7E0-4058-82A2-77E93748C936 | — | — | 0.861 |
| 2 | 47c0b7df-a564-4e71-8d90-ba07bac40f59 | — | — | 0.842 |
| 3 | SJEPD031429_D1.RNA-Seq | EPN | EPN Tumor | 0.842 |
| 4 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.816 |
| 5 | TCGA-E2-A1B0-01A-11R-A12P-07 | — | C | 0.811 |
| 6 | MNG402 | — | — | 0.803 |
| 7 | TCGA-BT-A20U-01A-11R-A14Y-07 | — | — | 0.802 |
| 8 | 2723b191-7c84-4edd-b0d0-da8ba4a1a894 | — | — | 0.801 |
| 9 | 34229BDA-4BF2-4537-A663-15896F6E269A | — | — | 0.798 |
| 10 | ERR2598197 | fetal | fetal | 0.791 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.477 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.438 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.411 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.402 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.396 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.391 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.383 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.368 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.366 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.331 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.327 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.292 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.266 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.264 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.237 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.221 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.181 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.177 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.176 | Idelalisib | — uncovered |